Heart Failure

New studies say restricting salt intake can reduce the risk of atrial fibrillation (AF) in certain patients, but cannot reduce the risks of morbidity and death in patients with heart failure.

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, emphasizes the importance of bringing heart health care to patients and meeting them where they are.

New research reveals that elevated lipoprotein(a) and oxidized phospholipids are independent risk factors for early-stage heart failure progression.

Patients with the highest biologically active adrenomedullin (bio-ADM) levels at baseline were 114% more likely to die from any cause or be readmitted to the hospital for heart failure within 6 months compared with patients with the lowest levels.

Adults aged 70 and older were significantly more likely to develop congestive heart failure if they also experienced olfactory impairment.

According to new research from Jordan, patients with both heart failure (HF) and diabetes had a higher prevalence of HF with preserved ejection fraction (HFpEF), elevated cholesterol, low-density lipoprotein, and impaired kidney function.

From 2015 to 2020, the number of patients opting for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) over redo surgical aortic valve replacement (SAVR) rose significantly, from 35.3% to 62.5%.

Patients taking semaglutide for a year saw significant improvements in exercise capacity and lost 2.9% more body weight compared with patients taking placebo.

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women's Health Week and every week.

Patients who responded positively to shunt treatment experienced more beneficial changes in their heart's structure and function compared with nonresponders.

Enhancing coordination of care has the potential to increase the value of heart failure care.

Eko Health's artificial intelligence (AI) tool can detect low ejection fraction in seconds via an Eko stethoscope, bringing earlier heart failure detection to routine checkups.

COVID-19 vaccination was associated with reduced risks of acute and post–acute COVID-19 heart failure, venous thromboembolism, and arterial thrombosis/thromboembolism.

However, researchers saw higher risks of respiratory failure, longer stays in the intensive care unit, increased hospitalizations, and elevated mortality rates in patients with heart failure with reduced ejection fraction (HFrEF) taking the antihypotensive medication.

Increased perceived economic burden (PEB) was associated with an increased risk of mortality and poorer health status among patients with acute decompensated heart failure (HF).

Research found that maternal loss of a partner or older child, as well as the loss of a close relative due to unnatural causes in the year before or during pregnancy, were linked to a heightened risk of heart failure in offspring.

This study was the first of its kind to explore how taking statin medication affects blood vessel function and exercise response in patients with heart failure with preserved ejection fraction (HFpEF), although the cohort only included 16 patients.

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

Increased daily step count was linked to reduced risks of overall heart failure (HF) and HF with preserved or reduced ejection fraction.

Among Medicare beneficiaries, implantation was especially frequent for female patients and those undergoing tricuspid valve replacement with or without concomitant left-sided heart surgeries.

Patients admitted to the hospital with acute decompensated heart failure (ADHF) who also had low muscle mass and hypoalbuminemia experienced a heightened mortality risk, suggesting skeletal muscle mass and serum albumin are important prognostic factors.

Researchers found TET2 clonal hematopoiesis of indeterminate potential (CHIP) to be an independent risk factor associated with incident heart failure with preserved ejection fraction (HFpEF).

A recent study found that use of optimal guideline-directed medical therapies after heart failure with reduced ejection fraction (HFrEF) diagnosis is low overall, but especially among female patients compared with male patients.

An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection fraction (HFimpEF).

The top 5 most-viewed heart failure (HF) content of the year focused on how walking can improve HF outcomes, a link between HF and carpal tunnel syndrome, and more.